Cite
Hiraoka A, Hirooka M, Koizumi Y, et al. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2016;47(6):558-565doi: 10.1111/hepr.12780.
Hiraoka, A., Hirooka, M., Koizumi, Y., Izumoto, H., Ueki, H., Kaneto, M., Kitahata, S., Aibiki, T., Tomida, H., Miyamoto, Y., Yamago, H., Suga, Y., Iwasaki, R., Mori, K., Miyata, H., Tsubouchi, E., Kishida, M., Ninomiya, T., Abe, M., Matsuura, B., Kawasaki, H., Hiasa, Y., & Michitaka, K. (2017). Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatology research : the official journal of the Japan Society of Hepatology, 47(6), 558-565. https://doi.org/10.1111/hepr.12780
Hiraoka, Atsushi, et al. "Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,6 (2017): 558-565. doi: https://doi.org/10.1111/hepr.12780
Hiraoka A, Hirooka M, Koizumi Y, Izumoto H, Ueki H, Kaneto M, Kitahata S, Aibiki T, Tomida H, Miyamoto Y, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Abe M, Matsuura B, Kawasaki H, Hiasa Y, Michitaka K. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2017 May;47(6):558-565. doi: 10.1111/hepr.12780. Epub 2016 Aug 30. PMID: 27480045.
Copy
Download .nbib